Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)
作者： Xiaofeng Wang , Kouros Owzar , Pankaj Gupta , Richard A. Larson , Flora Mulkey
DOI: 10.1111/BCP.12427
关键词:
摘要: Aims Vatalanib is an oral anti-angiogenesis agent that inhibits vascular endothelial growth factor receptor tyrosine kinases, which in patients showed auto induction of metabolism and variability pharmacokinetic (PK) disposition. The objective was to characterize the population PK time-dependent change vatalanib clearance assess exposure–toxicity relationship with myelodysplastic syndrome (MDS).
elsevier.com
sci-hub.se 参考文章(32)
Jerry W. Hussong, George M. Rodgers, Paul J. Shami, Evidence of increased angiogenesis in patients with acute myeloid leukemia Blood. ,vol. 95, pp. 309- 313 ,(2000) , 10.1182/BLOOD.V95.1.309
Teresa Padró, Sandra Ruiz, Ralf Bieker, Horst Bürger, Martin Steins, Joachim Kienast, Thomas Büchner, Wolfgang E. Berdel, Rolf M. Mesters, Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. ,vol. 95, pp. 2637- 2644 ,(2000) , 10.1182/BLOOD.V95.8.2637
T. Kerbusch, A. D. R. Huitema, J. Ouwerkerk, H. J. Keizer, R. A. A. Mathôt, J. H. M. Schellens, J. H. Beijnen, Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. British Journal of Clinical Pharmacology. ,vol. 49, pp. 555- 561 ,(2000) , 10.1046/J.1365-2125.2000.00217.X
Hassan, Svensson, Ljungman, Björkstrand, Olsson, Bielenstein, Abdel-Rehim, Nilsson, Johansson, Karlsson, A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. British Journal of Clinical Pharmacology. ,vol. 48, pp. 669- 677 ,(1999) , 10.1046/J.1365-2125.1999.00090.X
Jeanette M Wood, G Bold, Elizabeth Buchdunger, R Cozens, Stefano Ferrari, Jörg Frei, F Hofmann, Jürgen Mestan, H Mett, Terence O’Reilly, Elke Persohn, Johannes Rösel, Christian Schnell, David Stover, A Theuer, Harry Towbin, Fritz Wenger, K Woods-Cook, A Menrad, Gerhard Siemeister, M Schirner, Karl-Heinz Thierauch, Martin R Schneider, J Drevs, G Martiny-Baron, F Totzke, Dieter Marmé, PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration Cancer Research. ,vol. 60, pp. 2178- 2189 ,(2000)
Eveline S. J. M. De Bont, Stefano Rosati, Susan Jacobs, Willem A. Kamps, Edo Vellenga, Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. British Journal of Haematology. ,vol. 113, pp. 296- 304 ,(2001) , 10.1046/J.1365-2141.2001.02722.X
Ophelia Q P Yin, Yanfeng Wang, Horst Schran, A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human Subjects Clinical Pharmacokinectics. ,vol. 47, pp. 807- 816 ,(2008) , 10.2165/0003088-200847120-00005
William H. Pitlick, René H. Levy, Allan S. Troupin, John R. Green, Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine. Journal of Pharmaceutical Sciences. ,vol. 65, pp. 462- 463 ,(1976) , 10.1002/JPS.2600650344
S. Harmsen, I. Meijerman, R.F. Maas-Bakker, J.H. Beijnen, J.H.M. Schellens, PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors. European Journal of Pharmaceutical Sciences. ,vol. 48, pp. 644- 649 ,(2013) , 10.1016/J.EJPS.2012.12.019
Napoleone Ferrara, Keith Houck, LYN Jakeman, David W Leung, None, Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins Endocrine Reviews. ,vol. 13, pp. 18- 32 ,(1992) , 10.1210/EDRV-13-1-18